Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOFACITINIB Cause Maternal exposure timing unspecified? 272 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 272 reports of Maternal exposure timing unspecified have been filed in association with TOFACITINIB (XELJANZ XR). This represents 0.2% of all adverse event reports for TOFACITINIB.

272
Reports of Maternal exposure timing unspecified with TOFACITINIB
0.2%
of all TOFACITINIB reports
166
Deaths
190
Hospitalizations

How Dangerous Is Maternal exposure timing unspecified From TOFACITINIB?

Of the 272 reports, 166 (61.0%) resulted in death, 190 (69.9%) required hospitalization, and 180 (66.2%) were considered life-threatening.

Is Maternal exposure timing unspecified Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 272 reports have been filed with the FAERS database.

What Other Side Effects Does TOFACITINIB Cause?

Drug ineffective (30,382) Pain (21,659) Condition aggravated (16,925) Arthralgia (15,640) Fatigue (13,551) Rheumatoid arthritis (12,277) Off label use (11,736) Headache (11,061) Joint swelling (10,686) Malaise (9,040)

What Other Drugs Cause Maternal exposure timing unspecified?

RITUXIMAB (402) METHOTREXATE (350) ADALIMUMAB (343) DICLOFENAC (331) TOCILIZUMAB (327) HYDROXYCHLOROQUINE (309) FOLIC ACID (304) INFLIXIMAB (303) LEFLUNOMIDE (302) SECUKINUMAB (301)

Which TOFACITINIB Alternatives Have Lower Maternal exposure timing unspecified Risk?

TOFACITINIB vs TOFERSEN TOFACITINIB vs TOLNAFTATE TOFACITINIB vs TOLODODEKIN ALFA TOFACITINIB vs TOLTERODINE TOFACITINIB vs TOLVAPTAN

Related Pages

TOFACITINIB Full Profile All Maternal exposure timing unspecified Reports All Drugs Causing Maternal exposure timing unspecified TOFACITINIB Demographics